Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 30

Cited In for PubMed (Select 17947727)

1.

Human urothelial carcinoma cell response to Sunitinib malate therapy in vitro.

Wen J, Li HZ, Ji ZG, Jin J.

Cancer Cell Int. 2015 Feb 28;15:26. doi: 10.1186/s12935-015-0179-z. eCollection 2015.

2.

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature.

Gotink KJ, Broxterman HJ, Honeywell RJ, Dekker H, de Haas RR, Miles KM, Adelaiye R, Griffioen AW, Peters GJ, Pili R, Verheul HM.

Oncoscience. 2014 Dec 15;1(12):844-53. eCollection 2014.

3.

Combining targeted agents with modern radiotherapy in soft tissue sarcomas.

Wong P, Houghton P, Kirsch DG, Finkelstein SE, Monjazeb AM, Xu-Welliver M, Dicker AP, Ahmed M, Vikram B, Teicher BA, Coleman CN, Machtay M, Curran WJ, Wang D.

J Natl Cancer Inst. 2014 Oct 18;106(11). pii: dju329. doi: 10.1093/jnci/dju329. Print 2014 Nov. Review.

PMID:
25326640
4.

Current status of pharmacological treatment of colorectal cancer.

Akhtar R, Chandel S, Sarotra P, Medhi B.

World J Gastrointest Oncol. 2014 Jun 15;6(6):177-83. doi: 10.4251/wjgo.v6.i6.177.

5.

Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.

Hayashi H, Arao T, Matsumoto K, Kimura H, Togashi Y, Hirashima Y, Horita Y, Iwasa S, Okita NT, Honma Y, Takashima A, Kato K, Hamaguchi T, Shimada Y, Nakagawa K, Nishio K, Yamada Y.

Oncotarget. 2014 May 15;5(9):2588-95.

6.

Targeted therapy in gastrointestinal malignancies.

Chhatrala R, Thanavala Y, Iyer R.

J Carcinog. 2014 Feb 20;13:4. doi: 10.4103/1477-3163.127639. eCollection 2014. Review.

7.

Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.

Prasad V, Massey PR, Fojo T.

J Clin Oncol. 2014 May 20;32(15):1620-9. doi: 10.1200/JCO.2013.53.0204. Epub 2014 Apr 7.

PMID:
24711558
8.
9.

Blood-based biomarkers for the optimization of anti-angiogenic therapies.

Rabascio C, Bertolini F.

Cancers (Basel). 2010 May 28;2(2):1027-39. doi: 10.3390/cancers2021027.

10.

Future of targeted agents in metastatic colorectal cancer.

Burotto M, Hartley ML, Marshall JL, Pishvaian MJ.

Colorectal Cancer. 2012 Oct;1(5). doi: 10.2217/crc.12.52.

11.

From bench to bedside: lessons learned in translating preclinical studies in cancer drug development.

Lieu CH, Tan AC, Leong S, Diamond JR, Eckhardt SG.

J Natl Cancer Inst. 2013 Oct 2;105(19):1441-56. doi: 10.1093/jnci/djt209. Epub 2013 Sep 19. Review.

12.

Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?

Troiani T, Martinelli E, Morgillo F, Capasso A, Nappi A, Sforza V, Ciardiello F.

Ther Adv Med Oncol. 2013 Jan;5(1):51-72. doi: 10.1177/1758834012462462.

13.

Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy.

Wehler TC, Hamdi S, Maderer A, Graf C, Gockel I, Schmidtmann I, Hainz M, Berger MR, Theobald M, Galle PR, Moehler M, Schimanski CC.

Int J Colorectal Dis. 2013 Mar;28(3):385-98. doi: 10.1007/s00384-012-1551-2. Epub 2012 Sep 15.

14.

The multi-targeted kinase inhibitor sunitinib induces apoptosis in colon cancer cells via PUMA.

Sun J, Sun Q, Brown MF, Dudgeon C, Chandler J, Xu X, Shu Y, Zhang L, Yu J.

PLoS One. 2012;7(8):e43158. doi: 10.1371/journal.pone.0043158. Epub 2012 Aug 17.

15.

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.

Vlahovic G, Meadows KL, Uronis HE, Morse MA, Blobe GC, Riedel RF, Zafar SY, Alvarez-Secord A, Gockerman J, Starodub AN, Ready NE, Anderson EL, Bendell JC, Hurwitz HI.

Cancer Chemother Pharmacol. 2012 Jul;70(1):95-102. doi: 10.1007/s00280-012-1889-8. Epub 2012 May 26.

16.

A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.

Leong S, Eckhardt SG, Chan E, Messersmith WA, Spratlin J, Camidge DR, Diab S, Khosravan R, Lin X, Chow Maneval E, Lockhart AC.

Cancer Chemother Pharmacol. 2012 Jul;70(1):65-74. doi: 10.1007/s00280-012-1880-4. Epub 2012 May 24.

17.

Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer.

Mross K, Frost A, Scheulen ME, Krauss J, Strumberg D, Schultheiss B, Fasol U, B├╝chert M, Kr├Ątzschmer J, Delesen H, Rajagopalan P, Christensen O.

Vasc Cell. 2011 Jul 29;3:16. doi: 10.1186/2045-824X-3-16.

18.

Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents.

El Zouhairi M, Charabaty A, Pishvaian MJ.

Gastrointest Cancer Res. 2011 Jan;4(1):15-21.

19.

Personalized colon cancer care in 2010.

Catenacci DV, Kozloff M, Kindler HL, Polite B.

Semin Oncol. 2011 Apr;38(2):284-308. doi: 10.1053/j.seminoncol.2011.01.001. Review.

20.

Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells.

Yoon CY, Lee JS, Kim BS, Jeong SJ, Hong SK, Byun SS, Lee SE.

Korean J Urol. 2011 Jan;52(1):55-63. doi: 10.4111/kju.2011.52.1.55. Epub 2011 Jan 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk